Tibsovo (ivosidenib)

pCPA File Number: 22886

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy

Sponsor/Manufacturer:

Servier Canada Inc.

CDA-AMC Project Number:

PC0349-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable